Bol'noy arterial'noy gipertoniey, ne priverzhennyy lecheniyu


Cite item

Full Text

Abstract

Необходимость достижения контроля артериального давления (АД), подразумевающего поддержание его уровня на целевых значениях в течение всего периода между очередными приемами антигипертензивного препарата у всех пациентов, страдающих эссенциальной артериальной гипертонией (АГ), не вызывает сомнения. Обоснованность этой стратегии антигипертензивной терапии определяется прежде всего значительным снижением риска сердечно-сосудистых осложнений в той ситуации, когда уровень АД постоянно не превышает верхний предел целевого (140/90 мм рт. ст. для всех больных АГ).Повышение приверженности антигипертензивной терапии – один из наиболее реальных способов повышения ее эффективности. Очевидно, что добиться соблюдения рекомендаций можно только при сотрудничестве врача с пациентом, во многом достигающемся за счет подробного и вместе с тем доступного информирования последнего о цели лечения эссенциальной АГ, заключающейся в конечном итоге в увеличении продолжительности активной жизни. Минимизация выраженности нежелательных явлений, связанных с приемом антигипертензивных препаратов, сегодня вполне возможна за счет оптимизации режима их приема и подбора доз, а также тщательного учета противопоказаний к назначению определенного их класса, в том числе относительных. В свою очередь недостаточная приверженность антигипертензивной терапии приближает риск осложнений АГ у подобных пациентов к тем, кто вообще не получает лечения.

About the authors

V. V Fomin

ММА им. И.М.Сеченова

Клиника нефрологии, внутренних и профессиональных болезней им. Е.М.Тареева

S. V Moiseev

ММА им. И.М.Сеченова

Клиника нефрологии, внутренних и профессиональных болезней им. Е.М.Тареева

E. A Saginova

ММА им. И.М.Сеченова

Клиника нефрологии, внутренних и профессиональных болезней им. Е.М.Тареева

References

  1. ESH-ESC Guidelines Committee. ESH-ESC guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
  2. Frohlich E.D. The necessity for recognition and treatment of patients with “mild” hypertension. J Am Coll Cardiol 1999; 34: 1369–77.
  3. Hajjar I, Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199–206.
  4. Wolf-Maier K, Cooper R.S, Kramer H. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–17.
  5. Macedo M.E, Lima M.J, Silva A.O et al. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J Hypertens 2005; 23: 1661–6.
  6. Brindel P, Hanon O, Dartigues J.F et al. Prevalence, awareness, treatment, and control of hypertension in the elderly: the Three City study. J Hypertens 2006; 24: 51–8.
  7. Borghi C, Dormi A, D'Addato S et al. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens 2004; 22: 1707–16.
  8. Cuspidi C, Michev I, Lonati L et al. Compliance to hypertension guidelines in clinical practice: a multicentre pilot study in Italy. J Hum Hypertens 2002; 16: 699–703.
  9. Clause S.L, Hamilton R.A. Medicaid prescriber compliance with Joint National Committee VI Hypertension Treatment Guidelines. Ann Pharmacother 2002; 36: 1505–11.
  10. Degli Esposti E, Di Martino M, Sturani A. Risk factors for uncontrolled hypertension in Italy. J Hum Hypertens 2004; 18: 207–13.
  11. Фомин И.В., Мареев В.Ю., Фадеева И.П. и др. Истинная распространенность артериальной гипертонии и современное состояние гипотензивной терапии в Нижегородской области (данные регистра 1998 г.). Кардиология. 2000; 9: 33–7.
  12. Агеев Ф.Т., Мареев В.Ю., Патрушева И.Ф. Правильно ли мы выбираем гипотензивный препарат в повседневной амбулаторной практике и как исправить эту ситуацию? (По результатам исследования в Московском городском кардиодиспансере и многоцентровых исследований ФЛАГ и ФАГОТ). Сердце. 2003; 2 (4): 185–9.
  13. Беленков Ю.Н., Мареев В.Ю. Как мы лечим больных с сердечно - сосудистыми заболеваниями в реальной клинической практике. Тер. арх. 2003; 8: 5–11.
  14. Garg J.P, Elliott W.J, Folker A et al. Resistant hypertension revisited: a comparison of two university - based cohorts. Am J Hypertens 2005; 18 (5 Pt. 1): 619–26.
  15. Degli Esposti L, Degli Esposti E, Valpiani G et al. A retrospective, population - based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002; 24: 1347–57.
  16. Wetzels G.E, Nelemans P, Schouten J.S, Prins M.H. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22: 1849–55.
  17. Fodor G.J, Kotrec M, Bacskai K et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central - European study. J Hypertens 2005; 23: 1261–6.
  18. Salas M, In't Veld B.A, van der Linden P.D et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin Pharmacol Ther 2001; 70: 561–6.
  19. Alam M.G, Barri Y.M. Systolic blood pressure is the main etiology for poorly controlled hypertension. Am J Hypertens 2003; 16: 140–3.
  20. Chapman R.H, Benner J.S, Petrilla A.A et al. Predictors of adherence with antihypertensive and lipid - lowering therapy. Arch Intern Med 2005; 165: 1147–52.
  21. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure - lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004; 164: 722–32.
  22. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004; 2: CD004804.
  23. Iskedjian M, Einarson T.R, Mac Keigan L.D et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta - analysis. Clin Ther 2002; 24: 302–16.
  24. Chobanian A.V, Bakris G.L, Black H.R et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC VI Report. JAMA 2003; 289: 2560–71.
  25. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. Сердце. 2005; 4 (3): 120–6.
  26. Schoberberger R, Janda M, Pescosta W, Sonneck G. The COMpliance Praxis Survey (COMPASS): a multidimensional instrument to monitor compliance for patients on antihypertensive medication. J Hum Hypertens 2002; 16: 779–87.
  27. Akpa M.R, Agomuoh D.I, Odia O.J. Drug compliance among hypertensive patients in Port Harcourt, Nigeria. Niger J Med 2005; 14: 55–7.
  28. Black H.R, Elliott W.J, Grandits G et al. Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region. J Hypertens 2005; 23: 1099–106.
  29. Raji M.A, Kuo Y.F, Salazar J.A et al. Ethnic differences in antihypertensive medication use in the elderly. Ann Pharmacother 2004; 38: 209–14.
  30. Riehle J.F, Lackland D.T, Okonofua E.C et al. Ethnic differences in the treatment and control of hypertension in patients with diabetes. J Clin Hypertens (Greenwich) 2005; 7: 445–54.
  31. Lau D.S, Lee G, Wong C.C et al. Characterization of systemic hypertension in the San Francisco Chinese community. Am J Cardiol 2005; 96: 570–3.
  32. Cheung B.M, Wong Y.L, Lau C. Queen Mary Utilization of Antihypertensive Drugs Study: side - effects of antihypertensive drugs. J Clin Pharm Ther 2005; 30: 391–9.
  33. Zanchetti A, Hansson L, Menard J et al. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study for the HOT Study Group. J Hypertens 2001; 19: 819–25.
  34. Greenberg A. Diuretic complications. Am J Med Sci 2000; 319: 10–24.
  35. Burchardt M, Burchardt T, Baer L et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000; 164: 1188–91.
  36. Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 2005; 65: 773–86.
  37. Giuliano F.A, Leriche A, Jaudinot E.O et al. Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology 2004; 64: 1196–201.
  38. Roth A, Kalter-Leibovici O, Kerbis Y et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin Cardiol 2003; 26: 25–30.
  39. Aranda P, Ruilope L.M, Calvo C et al. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens 2004; 17: 139–45.
  40. Wannemacher A.J, Schepers G.P, Townsend K.A. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. Ann Pharmacother 2002; 36: 986–91.
  41. Elliott W.J. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther 1996; 60: 582–8.
  42. Opie L.H. Angiotensin converting enzyme inhibitors: the advance continues. 3d ed. UCT Press; 1999.
  43. Visser L.E, Stricker B.H, van der Velden J et al. Angiotensin converting enzyme inhibitor associated cough: a population - based case - control study. J Clin Epidemiol 1995; 48: 851–7.
  44. Mukae S, Itoh S, Aoki S et al. Association of polymorphisms of the renin - angiotensin system and bradykinin B2 receptor with ACE-inhibitor - related cough. J Hum Hypertens 2002; 16: 857–63.
  45. Kostis J.B, Shelton B, Gosselin G et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 1996; 131: 350–55.
  46. The HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–9.
  47. Luque C.A, Vazquez Ortiz M. Treatment of ACE inhibitor - induced cough. Pharmacotherapy 1999; 19: 804–10.
  48. Tenenbaum A, Grossman E, Shemesh J et al. Intermediate but not low doses of aspirin can suppress angiotensin - converting enzyme inhibitor - induced cough. Am J Hypertens 2000; 13: 776–82.
  49. David D, Jallad N, Germino F.W et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor - associated cough. Am J Ther 1995; 2: 806–13.
  50. Zanchetti A, Crepaldi G, Bond M.G et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS – a randomized double - blind trial. Stroke 2004; 35: 2807–12.
  51. Asselbergs F.W, Diercks G.F.H, Hillege H.L et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809–16.
  52. Pitt B, Poole-Wilson P.A, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.

Copyright (c) 2006 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies